PCM
CLVS

Prelude Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Prelude Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100
Closed -$1K – 2337
2020
Q1 		$1K Hold
100
– – ﹤0.01% 1359
2019
Q4 		$1K Buy
+100
New +$727 ﹤0.01% 1862
2019
Q3 		– Sell
-200
Closed -$3K – 2187
2019
Q2 		$3K Sell
200
-100
-33% -$1.81K ﹤0.01% 1563
2019
Q1 		$7K Buy
+300
New +$7.52K ﹤0.01% 1605

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Prelude Capital Management's CLVS Position: Q1 2020 in Review

Prelude Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 626 shares — an estimated $5.02K sold.

Prelude Capital Management first reported a position in CLVS in Q1 2015 and held it in 16 quarters. The position peaked at $1.66M in Q2 2017. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

  • Prelude Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 626 Clovis Oncology, Inc. shares in Q1 2020, an estimated $5.02K.
  • Prelude Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 16 quarters.
  • Prelude Capital Management's Clovis Oncology, Inc. position peaked at $1.66M in Q2 2017.
  • 154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.